
Arild Opheim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1412838/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. JAMA Psychiatry, 2017, 74, 1197.	11.0	200
2	Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. JAMA Psychiatry, 2019, 76, 127.	11.0	44
3	Effectiveness, safety and feasibility of extendedâ€release naltrexone for opioid dependence: a 9â€month followâ€up to a 3â€month randomized trial. Addiction, 2018, 113, 1840-1849.	3.3	20
4	Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). BMC Pharmacology & Toxicology, 2016, 17, 18.	2.4	18
5	No increased pain among opioidâ€dependent individuals treated with extendedâ€release naltrexone or buprenorphineâ€naloxone: A 3â€month randomized study and 9â€month openâ€treatment followâ€up study. American Journal on Addictions, 2019, 28, 77-85.	1.4	16
6	Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. European Addiction Research, 2019, 25, 303-309.	2.4	7
7	Adapting treatment length to opioidâ€dependent individuals' needs and preferences: a 2â€year followâ€up to a 1â€year study of extendedâ€release naltrexone. Addiction, 2021, 116, 2084.	3.3	5
8	The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse. European Addiction Research, 2022, 28, 56-67.	2.4	3
9	Risk of Relapse Among Opioidâ€Đependent Patients Treated With Extendedâ€Release Naltrexone or Buprenorphineâ€Naloxone: A Randomized Clinical Trial. American Journal on Addictions, 2021, 30, 453-460.	1.4	2